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Abstract 
Chemotherapy and radiotherapy are the most frequent treatment for patients suffering from malignant 
progression of cancer. Even though new treatments are now being implemented, administration of these 
chemotherapeutic agents remains as the first line option in many tumor types. However, the secondary effects 
of these compounds represent one of the main reasons cancer patients lose life quality during disease 
progression. Recent data suggests that Ocoxin, a plant extract and natural compound based nutritional 
complement rich in antioxidants and anti-inflammatory mediators exerts a positive effect in patients receiving 
chemotherapy and radiotherapy. This mixture attenuates the chemotherapy and radiotherapy-related side 
effects such as radiation-induced skin burns and mucositis, chemotherapy-related diarrhea, hepatic toxicity and 
blood-infection. Moreover, it has been proven to be effective as anticancer agent in different tumor models 
both in vitro and in vivo, potentiating the cytotoxic effect of several chemotherapy compounds such as Lapatinib, 
Gemcitabine, Paclitaxel, Sorafenib and Irinotecan. The aim of this review is to put some light on the potential of 
this nutritional mixture as an anticancer agent and complement for the standard chemotherapy routine. 
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Introduction 
Cancer patients diagnosed with primary and 
metastatic malignancies are treated with radiotherapy 
(RT) and a diverse group of chemical compounds, 
chemotherapeutics, which have been shown to be 
effective in controlling disease progression and, in 
some scenarios, eradicating the tumor mass [1-4]. 
Even though new successful treatment opportunities 
are now being implemented in several cancer types, 
such as immunotherapy for melanoma, colorectal 
cancer and hematological malignancies among others 
[5-7], the chemotherapy (CT) agents remain as the first 
option for many malignancies and a complement for 
those patients receiving immunotherapy regimens 
[8-10]. CT has been the only effective option for 
decades and its benefits are unquestionable. 
However, patients taking advantage from this 
treatment report a wide range of negative side effects 
that limit their life. One of the main goals of oncologist 
is to cope with the disease but providing good quality 
of life to cancer patients. 
The use of a diverse spectrum of nutritional 
compounds is a common complement for patients 
receiving CT and RT, including antioxidants, 
anti-inflammatory mediators and vitamins [11-16]. 
Antioxidants are one of the most routinely used 
complement, with moderately good results when 
dealing with treatment derived complications. To this 
respect, melatonin was proven effective in reducing 
the oral mucositis, which drives oral tissue 
inflammation and pain in head and neck cancer 
patients receiving CT and RT [17]. A high spectrum of 
antioxidants was proven to be effective dealing with 
CT-induced peripheral neuropathy (CINP) in patients 
suffering from Colorectal Cancer. Several studies 
reported attenuated CINP in patients receiving 
N-acetylcysteine, Goshajinkigan (GJG or TJ-107), a 
traditional Japanese herbal extract and Jianwei 
Hiangqi Guizhi Wuwu Decoction (JHGWD) a 
traditional Chinese medicine herbal extract, while 








Furthermore, the antioxidant effect of Sodium 
thiosulfate (STS) seems to be positive to revert a 
critical side effect of cisplatin treatment, as reduced 
hearing loss in head and neck cancer patients was 
recently reported [21]. 
Ocoxin, also known as Oncoxin or Ocoxin Oral 
solution, is an orally bioactive nutritional mixture 
composed by antioxidant and anti-inflammatory 
natural ingredients (Table 1) (Catalysis S.L), rich in 
green tea polyphenols, such as epigallocatechin-3 
gallate, glycyrrhizic acid, cinnamic acid and vitamin 
B6. These compounds have shown a positive effect 
when tested against cancer, reducing cancer stem cell 
markers in colon cancer and related to decreased 
colorectal cancer risk in humans [22-24]. Some Ocoxin 
ingredients such as glycyrrhizinic acid and previously 
mentioned green tea polyphenols exert immuno-
modulatory and anti-inflammatory functions [25-28], 
which may affect significantly to the positive response 
to this nutritional complement. Recent evidences 
describe the synergic effect of Ocoxin ingredient 
Ascorbic acid against lymphoma when combined 
with immunotherapy [29], thus, reinforcing the 
hypothesis that Ocoxin may act sinergically when 
administered with routinely used cytotoxic agents. 
 
Table 1. Ingredient composition of Ocoxin 
Average values (per 100 ml)  
Glycine 2.000 mg 
Glucosamine 2.000 mg 
Malic Acid 1.200 mg 
Arginine 640 mg 
Cysteine 204 mg 
monoammonium glycyrrinate 200 mg 
Ascorbic Acid 120 mg 
Zinc Sulfate 80 mg 
Green tea extract  25 mg 
calcium pantothenate 12 mg 
Piridoxine 4 mg 
Manganese sulphate 4 mg 
cinnamon extract 3 mg 
Sodium Benzoate 100 mg 
Potasium Sorbate 100 mg 
Maracuya Aroma 50 mg 
Sucralose 24 mg 
Folic Acid 400 µg 
cyanocobalamin 2 µg 
 
 
Evidences obtained during the last decade 
uncover the role of Ocoxin in improving the life 
quality of CT receiving cancer patients. Moreover, 
preclinical models of different cancer types point out 
Ocoxin as an effective anticancer agent and a good 
candidate to be tested as a complement for the CT and 
RT routines in the clinical practice. 
The aim of this review is to focus on the reported 
positive effects of Ocoxin during routine clinical 
cancer treatments and the effectiveness of using 
Ocoxin as anticancer compound and adjuvant for the 
CT and RT regimens. 
Ocoxin mitigates CT-related side effects 
in clinical trials 
While fighting against cancer, patients receiving 
doses of CT have to deal with different complications 
related to the treatment. These complications include 
depression, loss of appetite and the consequent 
weight loss, diarrhea, interrupted treatment routine 
due to the adverse effects and inflammation of the 
oral cavity. There are several nutritional complements 
that help mitigating these side effects, which influence 
both the quality of life of cancer patients and 
determine the viability of the established treatment 
length [12]. The composition of Ocoxin, rich in natural 
compounds with well-known antioxidant and 
anti-inflammatory effects, may give rise to improved 
CT-related response. Moreover, it is to note that 
Ocoxin has shown good results when administered as 
an adjuvant regimen in patients receiving CT. Even 
though there is still a lack of studies regarding Ocoxin 
bioavailability and metabolization, the observed 
benefits may encourage researchers to go into deep 
into these processes, in order to understand and apply 
this compound to a wide spectrum of patients. 
Ocoxin administration routine 
The administration of Ocoxin along the different 
clinical studies conducted is specified in Table 2. 
Briefly, all patients undergoing CT and RT routines 
were supplemented with 50 or 75 ml oral Ocoxin from 
the beginning of the anticancer treatment until the 
end of the RT and CT cycles. In one clinical study 
Ocoxin supplementation started one month before the 
anticancer treatment and was sustained for one 
month after the conclusion of RT and CT routines. 
Ocoxin was administered for 3 weeks after the 
conclusion of the standard treatments in another 
clinical study. The Ocoxin administration spectrum 
and anticancer treatment implemented for each 
clinical study is specified in Table 2. 
Ocoxin and depression 
Depression is a common undesired side effect of 
CT regimens. Interestingly, increased degrees of 
oxidative stress, which is one of the catalyzators of the 
antitumor effect of CT, are associated with depression 
and anxiety symptoms [30]. It is to note that Ocoxin 
when administered to cancer patients improved their 
quality of life [31, 32], which was accompanied by an 
increased optimism, therefore, reducing the number 
of episodes of depression [31]. Moreover, Kaidarova 
et al. (2019) described improved quality of life along 
with increased well-being in patients receiving 




Ocoxin supplementation, compared to that of patients 
without Ocoxin [33]. It is tempting to hypothesize that 
the antioxidant potential of Ocoxin could be critical 
for this reported improvement. Moreover, this finding 
goes in line with previous reports on the use of a wide 
spectrum of compounds with antioxidant effects to 
treat human depression, such as resveratrol [34]. 
Regarding to preclinical evidences, the same 
therapeutic effect was reported in different mice 
models, where a reduction in the depressive behavior 
was observed due to the reduction on the oxidative 
stress [35-37]. Along with oxidative stress, 
inflammation has also been postulated as one the 
promoters of depression [38]. In fact, it is related to 
depression observed in patients suffering from other 
nervous system pathologies, such as multiple sclerosis 
[39]. One of the standard treatments to cope with 
depression is the use of antidepressants. These 
psychoactive drugs exert their effect in part through 
the reduction of the production of pro-inflammatory 
cytokines such us interleukin-1 β (IL-1β), interleukin-6 
(IL-6) and tumor necrosis factor α (TNF-α) [40, 42], 
therefore, modulating immune responses. 
Interestingly, natural compounds such as curcumin 
and salidroside have shown antidepressant effect in 
stress-induced depression with reported decreased 
inflammatory IL-6 and TNF-α signals (42, 43], driving 
to immune regulation. A similar response was 
observed in patients suffering from other pathologies 
under Ocoxin regimen, reporting immunoregulatory 
properties and reducing TNF-α level [25]. 
Consequently, Ocoxin may alleviate depression in 
cancer patients reducing the inflammatory status and 
the oxidative stress mediated damage. 
Ocoxin and Karnofsky index 
The Karnofsky Performance Scale Index is a 
measurement tool to assess the functional impairment 
of patients. The aim of this index is to assess the 
prognosis of patients, which allows comparing 
different therapies and treatments. Petients with 
higher Karnofsky index show better prognosis. It is to 
note that Ocoxin administration along with CT 
resulted in 59,26% increase in Karnofsky index 
compared to 30,38 reported in patients receiving CT 
alone, suffering from different neoplasic diseases, 
such as head and neck, breast and uterine cervix 
cancer [31]. In concordance, other natural compounds 
have shown efficacy when using as adjuvant along 
with CT regimens, increasing the Karnofsky index in 
cancer patients, such as those suffering from Non 
Small Cell Lung Cancer (NSCLC) [44]. Therefore, this 
effect may be mediated by the overall improvement in 
health status and self-steem observed in patients 
receiving daily dose of Ocoxin as coadjuvant to CT. 
Ocoxin improves CT and RT related 
toxicity 
The chemotherapeutic anticancer treatments 
cause a significant toxicity to patients, limiting their 
ability to tolerate the established routine for the 
treatment of the diagnosed malignancies. Ocoxin has 
shown a positive effect in mitigating CT-related 
toxicity, allowing patients to tolerate better the RT. In 
fact, Ocoxin reduced the number and the intensity of 
adverse episodes in head and neck, breast and uterine 
cervix cancer patients [31]. These results were recently 
confirmed by Chon-rivas et al. (2018) in head and 
neck cancer [45]. They reported decreased RT 
interruptions and lower side effects related to CT and 
RT toxicity. Almost 50% of the anticancer drugs 
approved by the FDA mediate the production of 
reactive oxygen species (ROS) or reactive nitrogen 
species (RNS) [44], therefore, affecting dramatically 
the function of healthy cells. Interestingly, antioxidant 
and anti-inflammatory properties of Ocoxin may be 
behind this improved tolerance to anticancer 
therapies.
 
Table 2. Clinical studies reporting significant benefits in patients receiving Ocoxin (Oncoxin) as coadjuvant for routine anticancer 
treatments 
Reference Cancer type Reported benefits Dose and regimen 
31 Head and neck cancer;  
Breast cancer;  
Uterine cervix cancer 
Reduced depression cases;  
Increased optimism;  
Reduced CT-related toxicity;  
Fewer treatment interruptions;  
Increased patient weight;  
Reduced radiation side effects;  
Increased survival rate 
CT+RT;  
50 ml Oncoxin/day for 1 year 
61 HCC Increased patient survival;  
Increased appetite 
No other treatment;  
50 ml day of Oncoxin (3 months) 
45 Head and Neck cancer Reduced RT interruptions;  
Reduced RT-CT toxicity 
 
CT + RT;  
75 ml day Oncoxin-Viusid (30 days prior, during 
treatment and 30 days after treatment) 
33 Gastric cancer;  
NSCLC 
Improved quality of life;  
Increased body mass;  
CT + RT;  
50 ml Oncoxin/day for 20 days 




Improved hepatic function;  
Reduced hepatic toxicity 
55 Malignant neoplasms Reduced hepatic toxicity;  
Improved oral mucositis;  
Increased food intake 
CT + RD;  
50 ml Oncoxin/day for 20 days 
32 Cervical cancer Endometrial Adenocarcinoma Improved hepatic function;  
Reduced hepatic toxicity;  
Reduced adverse effects;  
Improved quality of life 
CT + RT + BT;  
75 ml Oncoxin Viusid/daily from the beginning of 
CT treatment until 3 weeks after CT routine end. 
 
 
To this respect, one of the side effects, 
CT-induced cognitive impairment (CICI), also known 
as “chemobrain” or “chemofog” is partly mediated by 
the ROS and reactive nitrogen species (RNS) 
produced by CT, inducing neuron death [46]. This 
neuronal death might be partially inhibited by the 
antioxidant effect of Ocoxin, conferring the patient a 
better cognitive and health status. 
CT-induced diarrhea (CID) is considered a 
reliable toxicity parameter in patients receiving CT 
[47]. CID is a usual side effect of several CT agents 
such as Sorafenib and Irinotecan. With respect to 
Irinotecan, the most studied agent regarding to side 
effects, it is provoked by the intestinal cell damage 
through 7-Ethyl-10-hydroxycamptothecin (SN-38) 
metabolite. SN-38 can induce ROS in healthy cells, as 
reported in hepatocytes increasing ROS plasma levels 
of Irinotecan receiving cancer patients [48]. Moreover, 
epithelial intestinal cells (IEC) enter DNA 
damage-mediated apoptosis process, which leads to 
ROS production [49]. This ROS cause severe damage 
to IEC, promoting both inflammation and epithelial 
basal cell death leading to diarrhea. It is tempting to 
hypothesize that the antioxidant activity of Ocoxin 
may inhibit this ROS-mediated mechanism in the 
intestinal track, reducing CID. Moreover, Ocoxin 
mediated anti-inflammatory potential may reduce 
gastrointestinal inflammation, mitigating diarrhea 
symptoms, as reported using a Cyclooxigenase-2 
inhibitor, Celecoxib [50]. 
Oral mucositis is a severe inflammation of the 
oral cavity leading to oral pain and ulcerative area 
presented in almost all patients receiving RT and in 40 
% of the patients receiving CT [51, 52]. This damage is 
partly mediated by inflammatory mediators such as 
IL-1β, TNF-α and inducible nitric oxidase sinthase 
(iNOS) [53, 54]. Interestingly, Ocoxin exerts a curative 
effect in patients suffering from this side effect, 
diminishing the ulcerative area and facilitating the 
healing of the affected tissue [55], therefore 
eliminating the pain related to eating and drinking. 
This effect may be due to the anti-inflammatory 
properties of Ocoxin, which confers the ability to 
inhibit TNF-α upregulation, as reported in other 
pathologies [25]. It is tempting to hypothesize that this 
effect may be mediated by Glucosamine present in 
Ocoxin, since its supplementation leads to 
downregulation of nuclear factor kappa-light-chain- 
enhancer of activated B cells (NF-κβ), which in turn 
decreased inflammatory mediators such as IL-1β and 
TNF-α [56]. On the other hand, antioxidant potential 
of Ocoxin may block the synthesis of ROS and NOS 
during mucositis, in concordance with other findings 
reporting improved oral pathology using natural 
compounds with antioxidant and anti-inflammatory 
properties [57, 58]. 
In line with this observation, the 
supplementation with epigallocatechin-3-gallate 
(EGCG), one of the main ingredients of Ocoxin, has 
proven effective to mitigate CT and RT induced 
inflammatory disorders in patients suffering from 
other cancers [59, 60]. Therefore, Ocoxin seems to 
improve the quality of life of patients, as reported by 
Kaidarova et al. (2019) in patients receiving adjuvant 
CT [33]. Using Ocoxin as a complement for the CT 
regimen of gastric cancer and NSCLC patients 
(XELOX and paclitaxel+carboplatin respectively), 
they observed improved quality of life, along with 
increased body mass, appetite and albumin levels. 
Interestingly, Ocoxin almost eradicated the hepatic 
toxicity of CT regimens in those patients, maintaining 
alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels unchanged in 80 to 90% 
of the subjects. Moreover, clinical trials are now 
running for the evaluation of Ocoxin as a CT 
complement to confirm not only its beneficial 
potential to improve mucositis but also to increase 
patient appetite and body mass (ClinicalTrials.gov 
Identifier: NCT03577535). 
Ocoxin increases patient survival 
To improve cancer patient’s life quality 
represents a very significant positive effect of Ocoxin. 
However, this compound seems to prolong patient’s 
life expectancy in combination with routine CT 
regimen. Al-Mahtab et al, (2015) reported a significant 
increase in terminal stage hepatocellular carcinoma 
(HCC) patient’s life expectancy. All the patients from 
control group receiving CT suffering from HCC died 
within 2 months, while 52% of adjuvant Ocoxin 
supplemented patients died the first two months of 
the study. Interestingly, 26% of Ocoxin supplemented 
patients lived for another 3 months, while 21% of 
Ocoxin having individuals prolonged their life for 9 




months [61]. This observation goes in line with that 
reported by Uddin et al. (2018) , observing increased 
survival rates in Ocoxin receiving patients from head 
and neck, breast and uterine cervix cancer compared 
to control group (87,65% vs 74,68%, respectively) [31], 
always under CT routine. In line with these findings, 
clinical trials using Melatonin as adjuvant to CT 
resulted in 1 year increased survival rate while 
promoting the regression of tumors [62]. The same 
effect was reported using melatonin in combination 
with cisplatin and etoposide for NSCLC, improving 
tumor regression and increasing 6% the 5-year 
survival rate [63]. It is tempting to hypothesize that 
the antioxidant and anti-inflammatory effect of 
Ocoxin reverts the undesired side effects of CT, which 
leads to improved overall physiology of patients 
undergoing anticancer treatments, prolonging their 
life expectancy.  
Immune response modulation is a common step 
during cancer [64, 65], and plays a critical role in 
disease progression. In fact, the inhibition of the 
antitumor immune response represents one of the 
hallmarks of cancer development [66, 68]. It is to note 
that Ocoxin has an immune activation effect, which is 
the opposite effect mediated by both tumor and 
tumor-activated stromal cells in the tumor micro-
environment [64, 65, 68]. Therefore, the activation of 
the immune response, along with the antioxidant and 
anti-inflammatory properties of Ocoxin may lead to 
reported increased survival in HCC, head and neck, 
breast and uterine cervix cancer patients. 
Which is still to be deciphered is the direct 
antitumor effect of Ocoxin in cancer patients. 
Interestingly, a significant anticancer effect has been 
observed in different preclinical in vitro and in vivo 
cancer models. These preclinical models have proven 
a synergic effect of Ocoxin with a wide spectrum of 
CT agents in vitro and in vivo, even reverting 
stromal-mediated chemorresistance. 
Evidences of the positive effect of Ocoxin 
in the liver metabolism in patients under 
CT regimens 
One of the main organs suffering from CT 
routines is the liver. This organ is the responsible of 
metabolizing anticancer drugs, making the liver 
function monitoring a required measure [69]. 
Decreased albumin levels reflect liver damage. 
Moreover, the National Cancer Institue (NCI) 
assessed liver damage based on the increased serum 
levels of liver enzymes ALT, AST, alkaline 
phosphatase (ALP), and γ-glutamyltransferase (GGT) 
[69]. Clinical studies using Ocoxin as coadjunvant for 
gastric cancer revealed a significant improvement 
regarding liver toxicity when combined with adjuvant 
CT. Ocoxin supplementation led to increased serum 
albumin levels compared to non-supplemented 
adjuvant CT receiving group [32]. Besides, Ocoxin 
abrogated hepatic-toxicity related ALT and AST 
enzyme increase in 92% of the patients under 
adjuvant CT regiment after 3 weeks of treatments, 
while only the AST and ALT levels of 50% of the 
patients from non-supplemented group remained 
unchanged. This reduced hepatic toxicity was further 
confirmed by Shumsky et al. (2019) in patients 
receiving Ocoxin to mitigate CT and RT related oral 
mucositis [55]. They reported 4 and 7-fold reduced 
ALT and AST levels in patients under Ocoxin 
supplementation compared to those receiving CT and 
RT. It is tempting to hypothesize that increased ROS 
levels, which are a common product of 
drug-mediated hepatic toxicity [70], damage liver 
cells, leading to liver toxicity. Therefore, the 
antioxidant effect of Ocoxin may prevent hepatic 
tissue damage, as observed with several antioxidants, 
such as glyzirrinic azid, one of the components of 
Ocoxin [71, 72]. 
Ocoxin mitigates the negative effects in 
hemoglobin and leukocyte counts in 
patients under CT regimens 
CT treatments have severe impact in the 
hemoglobin levels of individuals receiving these 
drugs, leading to anemia [73]. Different antioxidants 
have shown positive effects in hemoglobin levels 
during anticancer treatments [74]. In line with these 
findings, Ocoxin supplementation reduced this side 
effect, diminishing hemoglobin toxicity in 80% of the 
patients receiving adjuvant CT. However, only 58% of 
patients receiving adjuvant CT treatment without 
coadjuvant Ocoxin showed no toxicity [32]. Similar 
results were reported in cervical cancer and 
endometrial carcinoma patients receiving Ocoxin as 
coadjuvant for CT routines. Ocoxin mitigated the 
decrease in hemoglobin concentration upon treatment 
with adjuvant CT, RT and brachytherapy [32]. 
Interestingly, Ruiz-Lorente et al. (2020) concluded that 
Ocoxin was efficient in mitigating the reduction in 
platelet and leukocyte counts in the blood of adjuvant 
CT receiving patients, compared to that of adjuvant 
CT receiving patients with no Ocoxin 
supplementation [32]. 
The antitumor effect in preclinical in 
vitro and in vivo models of Ocoxin 
As previously mentioned, there is an increasing 
need to find new strategies to improve sensitivity to 
CT and to prevent the produced side effects on 
patients undergoing anticancer treatments. Natural 




products are being implemented with promising 
results as coadjuvant for CT, not only for their 
positive effect in mitigating side effects but also for 
their anticancer action. To this respect, Ocoxin is a 
mixture of several natural compounds, which has 
proven benefits treating cancer individually. Several 
in vitro studies carried out on murine and human cell 
lines of different cancer types, such as breast, liver 
metastasis of colorectal cancer, acute myeloid 
leukemia (AML), liver, lung, pancreatic cancer and 
glioblastoma demonstrated that Ocoxin reduces 
tumor cell viability in a dose dependent manner 
(Table 3) [75-81]. 
This cytotoxicity of Ocoxin against tumor cells is 
triggered, in part, by increasing apoptosis and 
decreasing the proliferation of tumor cells [75-77]. 
Supporting these results, different biological 
compounds, such as, flavonoids, green tea and 
curcumin among others, have demonstrated 
antitumor effects through the induction of growth 
arrest and apoptosis of cancer cells [82-84]. It has been 
shown that Ocoxin slows down cell cycle of tumor 
cells by arresting cells on G2/M phase in case of 
breast and SCLC and increasing cell population on 
Sub G1 and decreasing in S phase in case of colorectal 
carcinoma [75, 79, 76]. Supporting these observations, 
genistein, a soy-derived isoflavone induced cell cycle 
arrest at G1 and/or S phase in certain cancer cell lines 
and it is known to inhibit cancer cell growth through 
G2/M inhibition in cancer cells [85, 86]. Furthermore, 
Cianfruglia et al. (2019) reported that curcumin 
extract, which has the ability to suppress cell 
proliferation, induced apoptosis, inhibited 
angiogenesis and suppressed the expression of 
antiapoptotic proteins, inhibited cell proliferation by 
G2/M cell-cycle phase arrest [87- 91]. The same effect 
was uncovered using genistein. Genistein arrested the 
cell cycle of human urinary bladder carcinoma on 
G2/M phase by the down-regulation of cyclin A and 
cyclin B1, and up-regulation of Cdk inhibitor p21 [92]. 
Ocoxin seems to carry out cell cycle arrest by 
increasing the levels of the cell cycle inhibitor p27 
protein and decreasing the cell cycle regulator cyclin 
D1 and the tumor suppressor pRb protein levels [75, 
77, 79]. 
Furthermore, natural products are used as a 
coadjuvant therapy to improve and increase the 
tumor cell sensitivity to CT [93]. To this regard, 
vincristine is used to treat acute lymphocytic 
lymphoma and neuroblastoma. Bahmani et al. (2018) 
described that Centaurea albonitens extract enhance the 
cytotoxicity of vincristine without increasing normal 
cell toxicity [94]. Moreover, 5-fluorouracil (5-FU) is a 
CT used to treat several cancer types, such as, gastric, 
breast, liver and prostate [88-90]. In this way, 
curcumin and green tea, among others, have 
demonstrated efficacy by increasing the sensitivity of 
cancer cells and reducing the produced cytotoxicity 
[98, 99]. In this way, the co-treatment of curcumin and 
5- FU/oxaliplatin increased their synergistic 
antitumor efficacy in gastric cancer by activating the 
caspase 3, caspase 8 and 9 expression [99]. Moreover, 
the combination of curcumin with cisplating 
demonstrated a potent synergistic effect by activating 
caspase 3 in ovarian cancer [100]. Interestingly, 
Ocoxin increased in vitro the cytoxicity of first line 
chemoterapeutic agents, such as, irinotecan, 
paclitaxel, gemcitabine, Ara C, doxorubicin, 
fludarabine, sorafenib, docetaxel, vincristine, 
lapatinib and cisplatin by increasing the apoptosis of 
cancer cells [75, 77-81]. However, Ocoxin did not 
demonstrate any synergic effect with trastuzumab 
[75]. Furthermore, Ocoxin reduced the side effects 
produced by chemoterapy in mice [71], which is in 
line with described improved health status of patients 
treated with Ocoxin and with several studies carried 
out in animal models using natural compounds as 
coadjuvants [101,102]. 
Nowadays one of the major challenges to treat 
cancer is to fight resistance to the CT. This chemo-
resistance may be produced by the tumor host factors 
[103] or factors associated with tumor-tumor micro-
environment interactions [104]. The implication of the 
tumor microenvironment on the progression of the 
tumor and the chemoresistance nowadays is widely 
recognized [105-110]. The tumor microenvironment 
consists of tumor cells, vasculature, extracellular 
matrix (ECM), non-malignant cells, such as, stromal 
cells, tumor associated fibroblast (CAFs), immune 
cells and a complex signaling molecule network 
which include growth factors, cytokines, chemokines, 
and exosomes that sustain the internal connections of 
the microenvironment, [111,112]. Interestingly, 
Ocoxin modulates the tumor microenvironment 
through several pathways (Figure 1). 
CAFs, among others, participate in the 
development of tumor angiogenesis, metastasis, and 
chemo-resistance [112-114]. Moreover, CAFS secrete 
collagen that regulates the chemotherapeutic drug 
resistance of cancer cells [115]. Thus, the actual 
treatments could be directed not only to the tumor 
cells but also to block the interaction between CAFs 
and cancer cells to avoid the chemorresistance of the 
tumor. Interestingly, Ocoxin reverted the 
chemorresistance effect produced by CAFs on human 
pancreatic cells in vitro [81]. Moreover, hepatic stellate 
cells (HSCs) are hepatic myofibroblast-like cells that 
infiltrate the tumor and develop a pro-tumoral 
environment [116]. HSC burst liver metastasis 
through different mechanisms, such as, collagen 




deposition, immune suppressor cell recruitment and 
endothelial cell migration [117-120]. Interestingly, 
Ocoxin reduced the HSC infiltration into the tumor 
stroma of colorectal cancer liver metastasis, which 
was accompanied with decreased tumor burden [76]. 
This effect may be mediated by the reduction of 
inflammatory cytokines such as IL-6 and IL-1β, 
known to promote tumor growth, HSC mediated 
proliferation and increased ECM deposition. In fact, a 
similar reduction was reported in pancreatic cancer 
treated with conophylline, a plant derivate, where 
protumoral CAF effect was diminished [121]. 
As mentioned above, inflammation has been 
widely linked to cancer progression. In this way, one 
of the main source of inflammatory mediators in the 
tumor microenvironment are macrophages, cells of 
the innate immune system, which invade the 
precancerous tissue, and secrete factors to promote 
the tumor growth and metastasis [122,123]. Due to the 
anti-inflammatory properties of some natural 
products, their role as new and complementary 
treatments is being tested. For example, green tea 
extract administered to mice with nonalcoholic 
steatohepatosis has shown to inhibit the early 
oncogenic response [124]. In line with this results, 
Ocoxin regulated the cytokine milieu during liver 
colonization, decreased the pro-inflammatory IL1β, 
interferon gamma (IFNγ) and TNFα cytokine 
expression while reduced the macrophage infiltration 
into the tumor stroma and [76-78]. In fact, in 
concordance with this observation, Ocoxin impaired 
the polarization of macrophages into the 
proinflammatory M2 phenotype in a murine 
glioblastoma model, along with reduced tumor 
growth [125]. This effect may be mediated by the 
antioxidant effect of Ocoxin, which decreases ROS in 
macrophages in vitro, known to play an important role 
for M2 differentiation [126]. This result is in line with 
the use of chlorogenic acid in glioblastoma, with a 
potent antioxidant properties, that showed reduced 
tumor growth, mediated by a repolarization of M2 
macrophages into M1 [127]. Moreover, several 
antioxidants such as caffeic acid and butylated 
hydroxyl-anisole (BHA) have shown similar effects 
impeding M2 polarization. Therefore, Ocoxin impairs 
stromal cell recruitment affecting the generation of a 
proinflammatory and proangiogenic micro-
environment. 
 
Table 3. Preclinical studies reporting antitumor effects of Ocoxin and synergic effect with a wide variety of anticancer drugs 
Reference Cancer type In vitro results In vivo results 
75 HER2+ Breast cancer Reduced proliferation; 
 Increased apoptosis;  
Cell cycle arrest;  
Synergy with Lapatinib 
Decreased tumor volume 
76 CRC Reduced viability;  
Reduced migration;  
Cell cycle arrest 
Reduced liver metastasis;  
Increased CRC apoptosis;  
Reduced proliferation;  
Reduced CAF infiltration 
77 Acute Myeloid Leukemia Reduced proliferation;  
Cell cycle arrest;  
Synergy with Ara C;  
Dexorubicin and Fluradabine 
Reduced tumor volume;  
Reduced AML proliferation 
79 HCC Reduced HCC proliferation;  
Synergy with Sorafenib;  
Cell cycle retardation 
Reduced HCC proliferation 
78 CRC Reduced CRC viability;  
Synergy with Irinotecan 
Reduced liver metastasis;  
Increased CRC apoptosis;  
Reduced CRC proliferation;  
Reduced TAM infiltration;  
Synergy with Irinotecan regarding CRC proliferation 
80 SCLC Reduced SCLC proliferation; 
 Synergy with vincristine and docetaxel;  
Increased cell death;  
Cell cycle retardation 
 
Reduced tumor volume;  
Increased SCLC apoptosis;  
Reduced SCLC proliferation;  
Downregulation of angiogenesis-related genes in vivo in SCLC 
81 Pancreatic cancer Reduced cell viability;  
Cell cycle retardation;  
Synergy with Paclitaxel and Gemcitabine;  
Reduced fibroblast-mediated chemorresistance 
Reduced tumor markers 
125 Glioblastoma Reduced GBM viabity;  
Reduced CSC renewal ability; 
 Impaired macrophage polarization to M2 
Reduced GBM tumor growth;  










Figure 1. Ocoxin modulates the tumor microenvironment. Ocoxin treatment reduces the recruitment of tumor-promoting macrophages and fibroblasts into the developing 
tumor. Moreover, Ocoxin impairs reduces cell proliferation and increases apoptotic cancer cell death, leading to impaired tumor growth. 
 
Figure 2. Ocoxin exerts a wide spectrum of anticancer effects in vitro. On the one hand, reduces tumor cell proliferation and migration, tumor self-renewal potential, 
macrophage M2 polarization and the protective effect of fibroblasts in tumor cells exposed to anticancer drugs. On the other hand, increases tumor cell death by apoptosis, cell 
cycle arrest and sensitizes tumor cells to chemotherapy agents. 
 
In summary, Ocoxin impairs tumor 
development through a wide spectrum of antitumor 
effects (Figure 2). On the one hand, Ocoxin increased 
the cytotoxicity of anticancer agents and reduced the 
migration capacity of tumor cells. On the other hand, 
Ocoxin regulated the tumor microenviroment, by 
reducing the recruitment of different pro-tumoral 
cells and making the tumor more vulnerable and 
sensitive for CT. 
Conclusion and future perspectives 
The efficacy of the anticancer treatments and, 
therefore, the subsequent healing process of patients 
are strongly influenced by the nutritional state [12]. 
Taking into account that malnutrition is directly 
related to patient death when dealing with cancer 
malignancies, natural products and complements that 
could alleviate this physical condition should be 
considered as part of the treatment routine. Moreover, 
natural products with antioxidant and anti- 
inflammatory effect such as Ocoxin have been proven 
to be effective improving CT-related side effects and 
bursting antitumor effect of a wide spectrum of 
anticancer drugs. Therefore, if the ongoing clinical 
trials support these effects in patients suffering from 
different cancers, Ocoxin may be considered a good 
candidate as a complement of the routinely used RT 
and CT regimens. 
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